PROVIDENCE – Rubius Therapeutics, a Cambridge, Mass.-based biotech firm that develops and genetically engineers red blood cells for use in medications for rare diseases, cancer and autoimmune disorders, has been issued three new U.S. patents. Two of the issued patents are related to the matter and methods of use for an investigational cellular therapy for…
Want More Free?
To access 2 more articles, please log in or register for free.
Registered users get access to a limited number of free articles every month.